Annotation Detail for CACNA2D4

Basic Information
Top
| Pathway ID | Pathway Name |
|---|
| hsa04010 | MAPK signaling pathway |
| hsa05410 | Hypertrophic cardiomyopathy (HCM) |
| hsa05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) |
| hsa05414 | Dilated cardiomyopathy |
| hsa04260 | Cardiac muscle contraction |
| Desease Name |
|---|
| Retinal cone dystrophy 4 |
| Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
|---|
| D018038 |
Sodium Selenite |
Sodium Selenite results in decreased expression of CACNA2D4 mRNA | decreases expression | 18175754
|
| Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
|---|
| MESH:D019457 |
Chromosome Breakage |
|
Sodium Selenite |
5.66 | 15894690 |
| MESH:D003920 |
Diabetes Mellitus |
|
Sodium Selenite |
4.30 | 16285004 |
| MESH:D056486 |
Drug-Induced Liver Injury |
|
Sodium Selenite |
2.39 | 15131321 |
| MESH:D007333 |
Insulin Resistance |
|
Sodium Selenite |
3.60 | 14714311 |
| MESH:D016393 |
Lymphoma, B-Cell |
|
Sodium Selenite |
4.76 | 14737004 |
| MESH:D011471 |
Prostatic Neoplasms |
|
Sodium Selenite |
3.32 | 18760546 |
| OMIM:610478 |
RETINAL CONE DYSTROPHY 4 |
marker/mechanism |
|
| |
PharmGKB Accession:PA130546913
| Releated drug ID |
Related drug Name |
| PA452249 | antiarrhythmics, class i and iii |